PGHH - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.4
| Stock Code | PGHH | Market Cap | 32,181 Cr. | Current Price | 9,919 ₹ | High / Low | 14,543 ₹ |
| Stock P/E | 37.4 | Book Value | 287 ₹ | Dividend Yield | 1.71 % | ROCE | 104 % |
| ROE | 75.7 % | Face Value | 10.0 ₹ | DMA 50 | 11,454 ₹ | DMA 200 | 12,759 ₹ |
| Chg in FII Hold | -0.05 % | Chg in DII Hold | -0.02 % | PAT Qtr | 301 Cr. | PAT Prev Qtr | 210 Cr. |
| RSI | 15.6 | MACD | -458 | Volume | 13,149 | Avg Vol 1Wk | 25,267 |
| Low price | 9,889 ₹ | High price | 14,543 ₹ | PEG Ratio | -44.6 | Debt to equity | 0.00 |
| 52w Index | 0.64 % | Qtr Profit Var | 12.2 % | EPS | 265 ₹ | Industry PE | 41.8 |
📊 Procter & Gamble Hygiene and Health Care (PGHH) shows strong efficiency metrics with exceptional ROCE (104%) and ROE (75.7%), supported by a debt-free balance sheet. However, valuations are stretched (P/E 37.4 vs industry 41.8) and the PEG ratio (-44.6) indicates poor growth visibility relative to valuation. Dividend yield of 1.71% provides moderate income, but technical indicators (RSI 15.6, MACD negative) suggest bearish momentum in the short term.
💰 Ideal Entry Price Zone: ₹9,200 – ₹9,600 (closer to support levels and below DMA 50). Current price of ₹9,919 is near 52-week low, offering a fair entry for long-term investors.
📈 Exit Strategy / Holding Period: If already holding, investors should maintain a long-term horizon (5+ years) given strong efficiency and brand strength. Profit booking can be considered near ₹12,500–₹13,000 if recovery occurs. Long-term holders benefit from consistent dividends and strong fundamentals, despite near-term weakness.
✅ Positive
- Exceptional ROCE (104%) and ROE (75.7%) indicate superior efficiency.
- Debt-free balance sheet ensures financial stability.
- Dividend yield of 1.71% provides moderate income.
- Quarterly PAT growth of 12.2% shows earnings momentum.
⚠️ Limitation
- PEG ratio (-44.6) highlights poor growth-to-valuation balance.
- Valuations remain high relative to earnings (P/E 37.4).
- Low trading volumes compared to weekly average.
📉 Company Negative News
- Technical weakness (RSI 15.6, MACD negative) suggests oversold conditions.
- Minor decline in institutional holdings (FII -0.05%, DII -0.02%).
📈 Company Positive News
- Quarterly PAT improved from ₹210 Cr to ₹301 Cr.
- EPS of ₹265 supports long-term earnings visibility.
- Strong brand positioning in hygiene and healthcare products.
🏭 Industry
- Consumer healthcare and hygiene sector benefits from steady demand and brand loyalty.
- Industry P/E at 41.8 indicates PGHH trades at fair-to-premium valuation.
🔎 Conclusion
PGHH is a fundamentally strong company with exceptional efficiency and a debt-free balance sheet. While valuations are stretched and growth visibility is limited, long-term investors can hold for dividends and brand strength. New investors may enter near ₹9,200–₹9,600 for better risk-reward. Existing holders should maintain a long-term horizon, with partial profit booking near ₹12,500–₹13,000 if recovery occurs.